DOI · e01.org

Safety, Efficacy, Pharmacokinetic and Pharmacodynamic evaluation of YF-H-2015005 for mobilizing Hematopoietic stem cells in Non-Hodgkin's Lymphoma Patients

Weiping Liu, Yan Xie, Lingyan Ping, Min Jiang, Guanmin Zhang, Yimin Cui, Junyu Xu, Meng Chieh Wu, Xin Leng, Xiaopei Wang, Shufang Wang, Jun Zhu, Yuqin Song · Journal of Cancer · 2020

  • DOI 10.7150/jca.48748
  • Publisher Ivyspring International Publisher
  • Type article
  • Issued 2020

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · article · 2020

Abstract

Background: Targeting the interaction between SDF1 and CXCR4 may provide an opportunity to intervene in the hematopoietic stem cell mobilization process.Aim: The present study aimed to investigate the safety, efficacy, pharmacokinetic and pharmacodynamic profiles of YF-H-2015005, a CXCR4 antagonist, for the mobilization of hematopoietic stem cells (HSCs).Methods: A total of 15 patients with non-Hodgkin's lymphoma (NHL) eligible for autologous hematopoietic stem cell transplantation were enrolled.All patients achieved a partial or complete remission after the first-or second-line therapy.Granulocyte colony stimulating factor (G-CSF) was given in the morning for 8 consecutive days, and 0.24 mg/kg YF-H-2015005 was subcutaneously administered in the evening of the 4 th day of G-CSF treatment for up to four days.Apheresis was performed 9-10 hours following each dose of YF-H-2015005.Results: YF-H-2015005 was rapidly absorbed and eliminated, with Tmax and t1/2 of 0.5 and 5.04 ± 1.00 hours, respectively.Moreover, the mean peripheral blood CD34 + cell counts were elevated by 2.0-to 2.9-fold from 2 to 24 hours, and reached the maximum level of 76.5 ± 53.9 cells/kg at 10 hours after YF-H-2015005 treatment.Fourteen (93%) out of 15 NHL patients achieved a minimum target of ≥2×10 6 /kg CD34 + cells.Furthermore, there was no grades 3-4 treatment-related adverse event observed among these patients.Conclusion: YF-H-2015005 can serve as a safe, effective agent in combination with G-CSF for CD34 + hematopoietic progenitor cell mobilization in NHL patients.

Open the resolved locator · 10.7150/jca.48748

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 20:03 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v11p5635.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.